Discover investment opportunities in Best Stocks To Buy Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $1 using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Best Stocks To Buy Under $1 using our Smart AI Filter.
4 stocks found for "Best Stocks To Buy Under $1"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
1.08 Risk measure | ±71.6% Price volatility | -1.8 Valuation | 0.00% Annual yield | |||
1.41 Risk measure | ±67.6% Price volatility | -20.4 Valuation | 0.00% Annual yield | |||
1.56 Risk measure | ±83.0% Price volatility | -16.0 Valuation | 0.00% Annual yield | |||
1.24 Risk measure | ±72.2% Price volatility | -6.2 Valuation | 0.00% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Q: What are the growth prospects for Ayala Pharmaceuticals (AYLA)?
A: Ayala Pharmaceuticals focuses on developing targeted cancer therapies. The growth prospects hinge on the success of clinical trials and eventual FDA approvals. Investors monitor the biotech sector's performance and the company's pipeline progression for potential upswings.
Q: How does Aquestive Therapeutics (AQST) fare in terms of risk and volatility?
A: Biotech and pharmaceutical stocks, like AQST, often show high volatility due to drug approval unpredictabilities and market sentiment shifts. Investors should consider such volatility when evaluating risk profiles.
Q: What competitive advantages does Compugen (CGEN) offer in its sector?
A: Compugen leverages proprietary computational platforms to accelerate drug discovery, providing a technology-driven edge. This strategic advantage may position it favorably within the biotechnology field.
Q: How might Freeline Therapeutics (FRLN) perform under different economic conditions?
A: Freeline Therapeutics, as a gene therapy company, operates in a niche sector often less impacted by traditional economic cycles. Performance largely depends on R&D milestones rather than macroeconomic trends.
Q: What revenue opportunities are present for Avrobio (AVRO)?
A: Avrobio, focusing on gene therapies for rare diseases, expects revenue growth through successful commercialization of its therapies. However, this hinges on clinical trial success and regulatory approval.
Q: Is OncoCyte (OCX) a suitable choice for income-focused investors?
A: OncoCyte does not currently pay dividends, making it less appealing for income-focused investors. The company's reinvestment into research and development aims for future growth instead.
Cannabis grower Organigram Holdings Inc. OGI reported third-quarter 2025 net sales of $51.14 million, approximately $70.8 million Canadian dollars (CAD), up 72% year-over-year, beating the consensus of $48.33 million.
Read more